October 08, 2009 08:00 ET

The Medicines Company Announces Second New Patent Issuance for Angiomax®

PARSIPPANY, NJ--(Marketwire - October 8, 2009) - The Medicines Company (NASDAQ: MDCO) today announced that the United States Patent and Trademark Office (PTO) issued a new U.S. patent No. 7,598,343 ('343 patent). The '343 patent relates to a more consistent and improved Angiomax drug product made by processes described in the patent. The new patent has been listed in the U.S. Food and Drug Administration's publication "Approved Drug Products with Therapeutic Equivalence Evaluations," which is commonly known as the Orange Book, for Angiomax.

Angiomax is already protected under U.S. patent No. 5,196,404 ('404 patent), which covers the composition of matter of bivalirudin, and U.S. patent No. 7,582,727 ('727 patent), which relates to a more consistent and improved Angiomax drug product. The '404 patent expires on March 23, 2010; the '727 patent expires on July 27, 2028.

About The Medicines Company

The Medicines Company (NASDAQ: MDCO) is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax® (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex®(clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Medicines Company's website is www.themedicinescompany.com.

Statements contained in this press release about The Medicines Company that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include whether we are able to obtain or maintain patent protection for the intellectual property relating to the Company's products, whether the Company's products will advance in the clinical trials process on a timely basis or at all, whether clinical trial results will warrant submission of applications for regulatory approval, whether the Company will be able to obtain regulatory approvals, whether physicians, patients and other key decision-makers will accept clinical trial results, and such other factors as are set forth in the risk factors detailed from time to time in the Company's periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in the Company's Quarterly Report on Form 10-Q filed on August 10, 2009, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements.

Contact Information